- BIIB +0.37%
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Yahoo Finance · 16 hours ago
Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
- 219.72Add to watchlist+0.80 (+0.37%)At close: Wed. May 8, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open218.00High221.53Low217.00
- Mkt Cap31.99BP/E (TTM)27.47Div & YieldN/A & N/A
- Prev. Close218.9252 Wk. Low189.4452 Wk. High319.76
What analysts are sayingTop storiesRelated stocks
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan ...
Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases.
Breaking New Ground With Science. With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
The potential to transform the lives of patients is what drives us at Biogen. As a leading global biotechnology company, we work toward those once-in-a-lifetime moments that could become a historic point in our pursuit of innovative treatments.
Apr 25, 2023 · By Rebecca Robbins. April 25, 2023. The Food and Drug Administration on Tuesday authorized the first drug for a rare genetic form of the neurological disorder A.L.S., despite uncertainty about the...
